The most common side effects for the gefitinib group were elevated aminotransferase enzyme levels and rash, but six patients (5.3 percent) developed the serious condition interstitial lung disease, and one woman died of it. Noting that the disease was associated with gefitinib treatment, researchers stressed that "every patient treated with [this type of drug] should be monitored for this toxic effect." 吉非替尼组最常见的副作用是提升氨基转移酶酶水平及出疹，但六个病人 （5.3%） 间质性肺疾病发展情况严重并且一名妇女死于此种疾病。 因为注意到吉非替尼组与这种疾病相关，研究人员强调"每个病人 [用这种类型的药物治疗的] 应为注意此毒性副作用"。
Overall, the authors concluded, gefitinib was a safer and much more effective way to tackle this type of lung cancer in patients with the EGFR mutation, and that this treatment should be considered the first-line treatment for such patients. 综合而言，笔者总结：吉非替尼对于肺癌 EGFR 突变患者是一种更安全、 更有效的治疗方法，这种治疗应考虑为对这类病人的第一线治疗。